6月26日，Moderna盘中上涨5.23%，报66.485美元/股，成交额1.78亿美元。
消息面上，当日多家投行集中上调Moderna目标价：Piper Sandler将目标价从69美元上调至77美元，维持增持评级；杰富瑞将目标价从45美元上调至53美元，维持持有评级。多家机构同日发出积极信号，显著提振了投资者信心。
基本面方面，公司近期利好持续释放。其mRNA流感疫苗mFlusiva此前获FDA顾问委员会9-0全票推荐批准，若最终获批将成为美国首款mRNA季节性流感疫苗，FDA审批决定预计8月初做出。此外，公司已完成组织架构调整并任命新首席商务官，为未来多款新疫苗上市做准备。分析师目标价上调或反映了对公司产品管线商业化前景的重新评估。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.